Literature DB >> 11897565

Cerebrospinal fluid Abeta40 and Abeta42: natural course and clinical usefulness.

Mikio Shoji1.   

Abstract

Amyloid beta protein 40 (Abeta40) and 42 Abeta42, major components of senile plaque amyloids, are physiological peptides present in the brain, cerebrospinal fluid (CSF) and plasma. The levels of CSF Abeta40 and Abeta42(43) show a U-shaped natural course in normal aging. The increase of Abeta42(43) over 60 years of age is inhibited in Alzheimer's disease (AD). This specific alteration of CSF Abeta42(43) correlates with Abeta deposits in the AD brain providing a biological basis for a biomarker of AD. In the GTT2 study, assays of the CSF Abeta ratio ((Abeta40/ Abeta42(43)) showed a diagnostic sensitivity (59%) and specificity (88%) compared with non-AD type dementia and controls. The levels of the Abeta ratio increased from early to late stages of AD. Combination assays of CSF tau and Abeta ratio provided further efficient diagnostic sensitivity (81%) and specificity (87%). The reliability of the assay may prompt worldwide usage of these CSF biomarkers for Alzheimer's patients.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11897565     DOI: 10.2741/A826

Source DB:  PubMed          Journal:  Front Biosci        ISSN: 1093-4715


  14 in total

Review 1.  Hemoglobin-derived peptides as novel type of bioactive signaling molecules.

Authors:  Ivone Gomes; Camila S Dale; Kimbie Casten; Miriam A Geigner; Fabio C Gozzo; Emer S Ferro; Andrea S Heimann; Lakshmi A Devi
Journal:  AAPS J       Date:  2010-09-02       Impact factor: 4.009

2.  Deciphering the Biochemical Pathway and Pharmacokinetic Study of Amyloid βeta-42 with Superparamagnetic Iron Oxide Nanoparticles (SPIONs) Using Systems Biology Approach.

Authors:  Aman Chandra Kaushik; Ajay Kumar; Vivek Dhar Dwivedi; Shiv Bharadwaj; Sanjay Kumar; Kritika Bharti; Pavan Kumar; Ravi Kumar Chaudhary; Sarad Kumar Mishra
Journal:  Mol Neurobiol       Date:  2017-05-06       Impact factor: 5.590

3.  Effects of amyloid β-peptides and gangliosides on mouse neural stem cells.

Authors:  Yutaka Itokazu; Midori Kato-Negishi; Yoshihiko Nakatani; Toshio Ariga; Robert K Yu
Journal:  Neurochem Res       Date:  2013-07-14       Impact factor: 3.996

Review 4.  What is the dominant Abeta species in human brain tissue? A review.

Authors:  Gillian C Gregory; Glenda M Halliday
Journal:  Neurotox Res       Date:  2005       Impact factor: 3.911

5.  Amyloid β-peptide 1-42 modulates the proliferation of mouse neural stem cells: upregulation of fucosyltransferase IX and notch signaling.

Authors:  Yutaka Itokazu; Robert K Yu
Journal:  Mol Neurobiol       Date:  2014-01-17       Impact factor: 5.590

6.  Biological markers and Alzheimer disease: a canadian perspective.

Authors:  Hyman M Schipper
Journal:  Int J Alzheimers Dis       Date:  2010-08-08

7.  Beta-amyloid monomers are neuroprotective.

Authors:  Maria Laura Giuffrida; Filippo Caraci; Bruno Pignataro; Sebastiano Cataldo; Paolo De Bona; Valeria Bruno; Gemma Molinaro; Giuseppe Pappalardo; Angela Messina; Angelo Palmigiano; Domenico Garozzo; Ferdinando Nicoletti; Enrico Rizzarelli; Agata Copani
Journal:  J Neurosci       Date:  2009-08-26       Impact factor: 6.167

Review 8.  Role of cholesterol in APP metabolism and its significance in Alzheimer's disease pathogenesis.

Authors:  M Maulik; D Westaway; J H Jhamandas; S Kar
Journal:  Mol Neurobiol       Date:  2012-09-16       Impact factor: 5.590

Review 9.  Alzheimer's disease biomarker discovery in symptomatic and asymptomatic patients: experimental approaches and future clinical applications.

Authors:  Lap Ho; Hayley Fivecoat; Jun Wang; Giulio Maria Pasinetti
Journal:  Exp Gerontol       Date:  2009-09-29       Impact factor: 4.032

10.  Differences in the cellular uptake and intracellular itineraries of amyloid beta proteins 40 and 42: ramifications for the Alzheimer's drug discovery.

Authors:  Rajesh S Omtri; Michael W Davidson; Balasubramaniam Arumugam; Joseph F Poduslo; Karunya K Kandimalla
Journal:  Mol Pharm       Date:  2012-06-01       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.